E-QURE CORP. (OTCMKTS:EQUR) Files An 8-K Other EventsItem 8.01 Other Events
On February 1, 2017, E-Qure Corp., OTCQB: EQUR (the “Registrant”) was informed by its chairman and principal shareholder, Mr. Ron Weissberg, that because of his belief that the Registrant’s shares of common stock, par value $0.0001 (the “Shares”) were undervalued, he intends to purchase Shares in the open market and/or in privately negotiated transactions from persons other than the Registrant, having an aggregate market value of up to $100,000, at price up to $0.20 per Share. Mr. Weissberg further informed the Registrant that he would inform the Registrant if he determines, in his discretion, to adjust the purchase parameters either as to the amount of his purchase commitment or the price per Share of his intended Share purchases.
About E-QURE CORP. (OTCMKTS:EQUR)
E-Qure Corp. owns intellectual property (IP) of technology of wound healing device. The IP assets, including the wound healing device, are designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). The BST Device implements electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The BST Device, using electrodes affixed around the opposing sides of the wound, emits an electrical field around the wound and therefore mimics the electrochemical physiology principle and induces local cell regeneration. The BST Device is used to treat severe stage II, as well as stage III and IV wounds, including pressure ulcers, diabetic ulcers and venous ulcers. The BST Device is a device for adjunctive therapy in wound healing. The BST Device is able to automatically adjust the electric pulse amplitude based on a patient’s impedance reading. E-QURE CORP. (OTCMKTS:EQUR) Recent Trading Information
E-QURE CORP. (OTCMKTS:EQUR) closed its last trading session up +0.050 at 0.200 with 41,900 shares trading hands.